A new study finds that GLP-1 medicines, including Wegovy, may be effective for children as young as six, particularly for weight loss in those with obesity. Both outlets describe the research as adding to evidence that the drugs can work in younger patients, but they highlight that medical opinion is not settled on how widely they should be used.
The reporting also focuses on the concerns that accompany the results. ABC News presents the issue as a split among doctors about whether the findings should automatically translate into broader, routine prescribing for younger children. The Post similarly notes effectiveness while emphasizing that there are troubling side effects or concerns that complicate decisions for clinicians and families. Together, the articles frame the same central question—whether benefits in very young children outweigh safety and practical considerations—without agreeing on an immediate consensus on use.